Abstracts tagged "risk assessment"

Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium
Validation of Serious Adverse Event Reporting in a Multicenter Registry
Matthew Basiaga¹, Rajdeep Pooni², Caitlan Pinotti³, Lisa Buckley⁴, Alysha Taxter⁵ and CARRA Registry Investigators⁶, ¹Mayo Clinic, Rochester, MN, ²Stanford University, Palo Alto, CA, ³Duke, Durham, NC, ⁴Vanderbilt University Medical Center, Nashville, TN, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶CARRA, Washington, DC
Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…
Abstract Number: 0510 • ACR Convergence 2022
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Christina Charles-Schoeman¹, Ernest Choy², Iain B McInnes³, Eduardo Mysler⁴, Peter Nash⁵, Kunihiro Yamaoka⁶, Ralph Lippe⁷, Nasser Khan⁸, Anna K Shmagel⁹, Hannah Palac⁹, Jessica Suboticki¹⁰ and Jeffrey Curtis¹¹, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸AbbVie, Inc., Abbott Park, IL, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰AbbVie, Inc., Mettawa, IL, ¹¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…
Abstract Number: 0716 • ACR Convergence 2022
Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic
Jack Ellrodt¹, Emily G Oakes¹, Laura Kubzansky², Karestan Koenen², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: Posttraumatic Stress Disorder (PTSD), a complex psychiatric disorder that can result from experiencing or witnessing a traumatic event, such as an accident, assault, or…
Abstract Number: 1429 • ACR Convergence 2022
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
jacques-eric gottenberg¹, Nadir Mammar², Meriem Kessouri², Jeremie RUDANT², nada Assi³, Benjamin grenier³ and julien kirchgesner⁴, ¹Strasbourg University Hospital, Strasbourg, France, ²Pfizer, Paris, France, ³HEVA, Lyon, France, ⁴AP-HP, Paris, France
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…
Abstract Number: 0723 • ACR Convergence 2022
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Lea Hoisnard¹, Laura Pina Vegas², Rosemary Dray-Spira³, Alain Weill³, Mahmoud Zureik³ and Emilie sbidian⁴, ¹Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France, ²Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France, ⁴Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
Background/Purpose: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib…
Abstract Number: 1466 • ACR Convergence 2022
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Alice Barinotti¹, Massimo Radin¹, Irene Cecchi², Silvia Grazietta Foddai¹, Simone Baldovino¹, Elisa Menegatti¹, Daniela Rossi¹, Vittorio Modena¹, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Cardiovascular diseases (CVDs) represent one of the most life-threatening conditions that can affect SLE patients. Assessing the potential CVD risk of these patients is…
Abstract Number: 0732 • ACR Convergence 2022
Application of Natural Language Processing to Identify Varicella Zoster Infection in Clinical Notes
Austin Ho¹, Zara Izadi², Gabriela Schmajuk³, Jinoos Yazdany⁴, Suzanne Tamang⁵ and Milena Gianfrancesco⁶, ¹University of California, Berkeley, Berkeley, CA, ²University of California San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Stanford Center for Population Health Sciences, Redwood City, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Varicella zoster virus (VZV) infection can be associated with significant morbidity in immunosuppressed individuals. However, infections of VZV are often documented in unstructured fields…
Abstract Number: 1486 • ACR Convergence 2022
Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Vinod Chandran³, Paula Harvey⁴, Richard Cook², Vincent Piguet⁴, Dafna Gladman⁵ and Lihi Eder⁶, ¹University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Women's College Hospital, Toronto, ON, Canada, ⁵Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cardiovascular risk in patients with psoriatic disease (PsD) may be underestimated by conventional scoring systems. We derived and internally validated a 5-year disease-specific cardiovascular…
Abstract Number: 0840 • ACR Convergence 2022
Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy
Kinjal Vasvada, Laith Jazrawi and Jonathan Samuels, NYU Langone Health, New York, NY
Background/Purpose: Recent literature suggests that rheumatic disease patients hold most immunosuppressive (IS) medications before and after joint replacement surgery, to prevent infections and other complications.…
Abstract Number: 1512 • ACR Convergence 2022
What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain
Nelly Ziade¹, Avin Maroof², Bassel Elzorkany³, Nizar Ani⁴, ASAL ADNAN RIDHA⁵, Ahmed Abogamal⁶, Sahar Saad⁷, Lina El Kibbi⁸, Samar Al emadi⁹, Atheer Al Ansari¹⁰, Antonella Abi Najm¹, Tonine Younan¹, Khalil Kharrat¹, Joseph Maarrawi¹, Amer Sebaaly¹, Rami El Rachkidi¹, Torsten Witte¹¹ and Xenofon Baraliakos¹², ¹Saint-Joseph University, Beirut, Lebanon, ²Rizgary Teaching Hospital - Erbil, Erbil, Iraq, ³Department of Rheumatology, Cairo University, Cairo, Egypt, ⁴Baghdad College of Medicine, Baghdad, Iraq, ⁵Baghdad Teaching Hospital, Baghdad, Iraq, ⁶Saudi German Hospital Dubai, Dubai, United Arab Emirates, ⁷King Hamad University Hospital, Al Sayh, Bahrain, ⁸Specialized Medical Center, Riyadh, Saudi Arabia, ⁹Hamad Medical Corporation, Doha, Qatar, ¹⁰Mediclinic, Abu Dhabi, United Arab Emirates, ¹¹MH-Hannover, Hannover, Germany, ¹²Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The diagnosis of axial spondyloarthritis (axSpA) is often delayed, due to the referral issues and, in certain regions of the world, the low prevalence…
Abstract Number: 0900 • ACR Convergence 2022
Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, Jon Giles², George Reed³, Kevin Kane⁴, Jeffrey Curtis⁵ and Joel Kremer⁶, ¹CorEvitas, LLC, Waltham, MA, ²Columbia University, New York, NY, ³The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁴University of Massachusetts, Worcester, MA, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Cardiovascular (CV) risk in RA is increased due to interaction between traditional risk factors and systemic inflammation. The purpose of this analysis was to…
Abstract Number: 1526 • ACR Convergence 2022
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
cosimo bruni¹, Lorenzo Tofani¹, Håvard Fretheim², Sophie Liem³, Arthiha Velauthapillai⁴, Hilde Jenssen Bjørkekjær⁵, Imon Barua², Ilaria Galetti⁶, Alexandru Garaiman⁷, Mike Becker⁷, Anna-Maria Hoffmann-Vold², Jeska de Vries-Bouwstra⁸, Madelon Vonk⁹, Jörg Distler¹⁰, Marco Matucci-Cerinic¹ and Oliver Distler⁷, ¹University of Florence, Florence, Italy, ²Oslo University Hospital, Oslo, Norway, ³LUMC, Leiden, Netherlands, ⁴Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, ⁵Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ⁶Gruppo Italiano Lotta alla Sclerodermia (GILS), Milano, Italy, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁰Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…
Abstract Number: 0911 • ACR Convergence 2022
Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis
Iris Navarro-Millan¹, Mackenzie Brown², Yuliana Domínguez Páez³, Geyanne Lui⁴, Joan Weiner¹, Shelley fritz¹, Tien Sydnor-Campbell⁵, Aberdeen Allen⁶, Assem Jabri¹, Shilpa Venkatachalam⁷, Kelly Gavigan⁸, William Benjamin Nowell⁹, Jeffrey Curtis¹⁰, Liana Fraenkel¹¹ and Monika Safford¹, ¹Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, Brooklyn, NY, ³Weill Cornell Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Weill Cornell Medicine, Philedelphia, ⁶Weill Cornell Medicine, Parlin, ⁷Global Healthy Living Foundation, New York, NY, ⁸Global Healthy Living Foundation, Upper Nyack, NY, ⁹Global Healthy Living Foundation, Nyack, NY, ¹⁰University of Alabama at Birmingham, Hoover, AL, ¹¹Berkshire Medical Center, Lenox, MA
Background/Purpose: Only 37% of patients with rheumatoid arthritis (RA) receive screening for cardiovascular disease (CVD) despite their high risk. To improve CVD prevention, we designed…
Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].